ATE312097T1 - Polymorphe und andere kristalline formen von cis- ftc - Google Patents

Polymorphe und andere kristalline formen von cis- ftc

Info

Publication number
ATE312097T1
ATE312097T1 AT02748367T AT02748367T ATE312097T1 AT E312097 T1 ATE312097 T1 AT E312097T1 AT 02748367 T AT02748367 T AT 02748367T AT 02748367 T AT02748367 T AT 02748367T AT E312097 T1 ATE312097 T1 AT E312097T1
Authority
AT
Austria
Prior art keywords
ftc
cis
forms
manufacture
polymorphods
Prior art date
Application number
AT02748367T
Other languages
German (de)
English (en)
Inventor
Kenneth R Phares
Devalina Law
Yuerong Hu
Original Assignee
Gilead Sciences Inc
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Abbott Lab filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ATE312097T1 publication Critical patent/ATE312097T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02748367T 2001-03-01 2002-03-01 Polymorphe und andere kristalline formen von cis- ftc ATE312097T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27256001P 2001-03-01 2001-03-01
US30960501P 2001-08-02 2001-08-02
PCT/US2002/006184 WO2002070518A1 (en) 2001-03-01 2002-03-01 Polymorphic and other crystalline forms of cis-ftc

Publications (1)

Publication Number Publication Date
ATE312097T1 true ATE312097T1 (de) 2005-12-15

Family

ID=26955597

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02748367T ATE312097T1 (de) 2001-03-01 2002-03-01 Polymorphe und andere kristalline formen von cis- ftc
AT05076347T ATE383355T1 (de) 2001-03-01 2002-03-01 Polymorph und andere kristallinische formen von zusammen-ftc

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05076347T ATE383355T1 (de) 2001-03-01 2002-03-01 Polymorph und andere kristallinische formen von zusammen-ftc

Country Status (14)

Country Link
US (3) US6723728B2 (enExample)
EP (3) EP1903041B1 (enExample)
JP (4) JP5105689B2 (enExample)
KR (4) KR101150250B1 (enExample)
CN (4) CN102911165B (enExample)
AT (2) ATE312097T1 (enExample)
AU (1) AU2002335489B2 (enExample)
CA (4) CA2788498C (enExample)
CY (2) CY1107983T1 (enExample)
DE (2) DE60224592T2 (enExample)
DK (2) DK1574512T3 (enExample)
ES (3) ES2253544T3 (enExample)
PT (2) PT1903041E (enExample)
WO (1) WO2002070518A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60224592T2 (de) * 2001-03-01 2009-01-29 Abbott Laboratories, Abbott Park Polymorphe und andere kristalline Formen von cis-FTC
TWI244393B (en) * 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
DE602004014470D1 (de) 2003-01-14 2008-07-31 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US20060014949A1 (en) * 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
WO2009005338A2 (en) * 2007-07-05 2009-01-08 Ultimorphix Technologies B.V. Solid forms ult-i, ult-2 and ult-3 of emtricitabine
EP2350065A1 (en) 2008-11-12 2011-08-03 Lupin Ltd. A novel polymorph of emtricitabine and a process for preparing of the same
EP2454244B1 (en) 2009-07-15 2013-06-26 Lupin Limited An improved process for preparation of efavirenz

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4476248A (en) 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
US5684153A (en) 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
DE3485225D1 (de) 1983-08-18 1991-12-05 Beecham Group Plc Antivirale guanin-derivate.
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
EP0380558A4 (en) 1987-09-22 1991-07-31 The Regents Of The University Of California Liposomal nucleoside analogues for treating aids
US6175008B1 (en) * 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
NZ228645A (en) 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) * 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5700937A (en) 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
WO1991018914A1 (en) 1990-05-29 1991-12-12 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
DE69115694T2 (de) 1990-06-13 1996-10-17 Arnold Newton Mass. Glazier Phosphorylierte prodrugs
US5674849A (en) 1990-10-24 1997-10-07 Allelix Biopharmaceuticals Inc. Anti-viral compositions
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US6228860B1 (en) * 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5179104A (en) 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
IT1244501B (it) 1991-03-22 1994-07-15 Sigma Tau Ind Farmaceuti Derivati amminoacilici e oligopeptidici dell'allopurinolo dotati di attivita' immunostimolante e composizioni farmaceutiche che li contengono
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
AU668873B2 (en) 1991-07-12 1996-05-23 Chimerix, Inc. Antiviral liponucleosides: treatment of hepatitis B
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
GB9116601D0 (en) 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
EP0746319A4 (en) 1993-05-12 1997-11-05 Karl Y Hostetler ACYCLOVIR DERIVATIVES FOR TOPICAL USE
GB9311709D0 (en) 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
US5808040A (en) 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
SE503154C2 (sv) * 1995-03-10 1996-04-01 Tony Wiseby Anordning vid sikte för pilbåge
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
DE19543707A1 (de) * 1995-11-23 1997-05-28 Inst Neue Mat Gemein Gmbh Verfahren zum Konservieren von Papier
GB9525606D0 (en) 1995-12-14 1996-02-14 Iaf Biochem Int Method and compositions for the synthesis of dioxolane nucleosides with › - configuration
WO1998023285A1 (en) 1996-11-29 1998-06-04 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis b
TW318283B (en) 1996-12-09 1997-10-21 United Microelectronics Corp Multi-level read only memory structure and manufacturing method thereof
CA2287370C (en) 1997-03-19 2010-02-09 Emory University Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides
MXPA01001552A (es) * 1998-08-12 2004-08-23 Triangle Pharmaceuticals Inc Metodo de elaboracion de 1,3-oxatiolan-nucleosidos.
WO2000022157A1 (en) 1998-10-09 2000-04-20 Altus Biologics Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
DE60224592T2 (de) 2001-03-01 2009-01-29 Abbott Laboratories, Abbott Park Polymorphe und andere kristalline Formen von cis-FTC
CA2351049C (en) * 2001-06-18 2007-03-13 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers

Also Published As

Publication number Publication date
CA2690137C (en) 2012-11-13
CA2690137A1 (en) 2002-09-12
CA2788498A1 (en) 2002-09-12
KR20100091265A (ko) 2010-08-18
ES2253544T3 (es) 2006-06-01
EP1574512B1 (en) 2008-01-09
KR20080065316A (ko) 2008-07-11
CA2439831A1 (en) 2002-09-12
US20050026934A1 (en) 2005-02-03
US8637535B2 (en) 2014-01-28
DE60224592D1 (de) 2008-02-21
EP1389207B1 (en) 2005-12-07
KR100927024B1 (ko) 2009-11-17
KR101150250B1 (ko) 2012-06-12
EP1389207A1 (en) 2004-02-18
CY1107913T1 (el) 2013-09-04
DE60207850T2 (de) 2006-08-10
CN102911166A (zh) 2013-02-06
US7544692B2 (en) 2009-06-09
ES2537007T3 (es) 2015-06-01
EP1574512A1 (en) 2005-09-14
JP2013040192A (ja) 2013-02-28
DK1574512T3 (da) 2008-03-03
KR20080065317A (ko) 2008-07-11
KR101015510B1 (ko) 2011-02-16
CN1503796B (zh) 2012-07-04
DE60207850D1 (de) 2006-01-12
CA2439831C (en) 2010-01-12
JP5105689B2 (ja) 2012-12-26
ES2299950T3 (es) 2008-06-01
US6723728B2 (en) 2004-04-20
CN102911165A (zh) 2013-02-06
CN102942563A (zh) 2013-02-27
DE60224592T2 (de) 2009-01-29
PT1903041E (pt) 2015-06-23
EP1903041B1 (en) 2015-02-18
US20030060645A1 (en) 2003-03-27
DK1389207T3 (da) 2006-04-18
JP2004530660A (ja) 2004-10-07
CA2867970A1 (en) 2002-09-12
WO2002070518A1 (en) 2002-09-12
AU2002335489B2 (en) 2008-06-05
JP2009197005A (ja) 2009-09-03
ATE383355T1 (de) 2008-01-15
CN102911165B (zh) 2016-08-17
PT1574512E (pt) 2008-03-05
CY1107983T1 (el) 2013-09-04
CN1503796A (zh) 2004-06-09
US20090306114A1 (en) 2009-12-10
EP1903041A3 (en) 2008-04-23
EP1903041A2 (en) 2008-03-26
KR20040002871A (ko) 2004-01-07
JP2015028045A (ja) 2015-02-12
CN102911166B (zh) 2016-08-17
CA2788498C (en) 2016-02-16

Similar Documents

Publication Publication Date Title
CY1107913T1 (el) Πολυμορφικες και αλλες κρυσταλλικες μορφες cis-ftc
NO20031471L (no) Glykoformer av faktor VII
NO20012966D0 (no) Kondenserte 1,2,4-tiadiazinderivater, deres fremstilling og anvendelse
SE0102315D0 (sv) Compounds
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
PL366590A1 (en) Novel compounds as anti-inflammatorz, immunomodulatory and anti-proliferatory agents
CY1110240T1 (el) Νεα παραγωγα 2η-πυριδαζινο-3-ονης, φαρμακευτικες συνθεσεις που τα περιεχουν και μεθοδος για την παρασκευη του δραστικου συστατικου
CO5261589A1 (es) Compuestos heterociclicos, su produccion y su utilizacion
WO2005063734A3 (de) Substituierte thiophene
DE60137364D1 (de) Kristalline formen von atorvastatin
DE60330757D1 (de) Verwendung von pyridylamiden als angiogenesehemmer
CA2388142A1 (en) Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
CA2424470A1 (en) Treatment of gastrointestinal stromal tumors
MXPA05002442A (es) Imidazolopiridinas y metodos para la elaboracion y uso de las mismas.
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
DE602005025977D1 (de) Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
EA200400352A1 (ru) Органолептически приемлемые распадающиеся во рту композиции
WO2005004805A3 (en) Thermally stable crystalline epirubicin hydrochloride and method of making the same
MY141583A (en) Novel fused heterocycles and uses thereof
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
ATE501153T1 (de) Kristallisation von festen formen von clopidogreladditionssalzen
WO2006072458A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
JP2003516941A5 (enExample)
EA200701687A1 (ru) Гидрохлорид аморфного лерканидипина
RU93045711A (ru) Нейролептические пергидро-1h-пиридо(1,2-a)пиразины, способ их получения, фармацевтическая композиция, способ лечения

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1389207

Country of ref document: EP